AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01619761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer Cell Therapy
Description: Given IV
Study NCT01619761 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01619761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01619761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT01619761 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo allogeneic umbilical cord blood transplant
Study NCT03751371 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with HWA device
Description: Gait assessments will be conducted on participants randomized to the Trained group first during unassisted walking followed by HWA-assisted walking. Participants randomized to the Trained group will receive physical therapist supervised home and community-based walking training wearing the HWA device 2 times per week for 45-60 minutes for 8 weeks. Training will consist of walking in and outside of the home while encouraging larger and more symmetrical steps with practice of activities that challenge the person's balance and motor control. Rest breaks will be allowed as needed. If the therapist is unable to adjust the HWA to provide a safe gait pattern, the session will be ended and the device removed.
Study NCT03751371 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: The Untrained group will continue their usual daily activities including any exercise regimen that they typically perform. However, they will be asked not to start any new exercise program during the study period.
Study NCT02477488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
Study NCT01433406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Study NCT03269773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-AD Inj.
Description: 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5 mL).~Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL
Study NCT03269773 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.3mL of the following study drug is injected respectively into both upper arms, both thighs, and abdomen (total of 5 regions) as a single dose (total 1.5mL)
Study NCT00625586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RAV12
Description: RAV12 at 0.375 mg/kg weekly escalated to 0.75 mg/kg weekly, intravenously.
Study NCT00625586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly, intravenously
Study NCT00148031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon and Ribavirin
Description: Both groups with receive the same medical intervention but offered at different locations
Study NCT00148031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon and Ribavirin
Description: Both groups with receive the same medical intervention but offered at different locations
Study NCT00148031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial
Description: Assessment of the likelihood of HCV treatment initiation and completion
Study NCT00148031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial
Description: Assessment of the likelihood of HCV treatment initiation and completion
Study NCT00148031 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-site (MMT Clinic) HCV evaluation and treatment
Description: Standard HCV treatment with Pegylated Interferon and Ribavirin
Study NCT00148031 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Off-site HCV evaluation and treatment
Description: Standard HCV treatment with Pegylated Interferon and Ribavirin
Study NCT03652389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MJS Diabetes
Description: patients will receive and respond to daily PRO (patient recorded outcomes) via text messages and report SMBG (self monitoring blood glucose), if insulin dependent, over the course of a 12 month period. They will also receive feedback and motivational messages based on patterns of their PROs
Study NCT00838812 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: application of the topic gel
Description: Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
Study NCT04352543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Video Game Exercise
Description: Play during 30 minutes in the easy level
Study NCT04352543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill walking exercise
Description: 30 minutes (65 - 75% heart rate maximal)
Study NCT04352543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary Behavior
Description: Quiet Rest: 30 minutes
Study NCT01116388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GFCF product with GFCF diet
Description: Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.~Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks.
Study NCT01116388 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: product containing gluten and casein (milk protein) with GFCF diet
Description: Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.~Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks
Study NCT00243867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxoprexin
Description: 6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
Study NCT00243867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxoprexin
Description: 6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
Study NCT01759342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT01759342 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Study NCT01759342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Study NCT01759342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility and postural exercise
Study NCT01759342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance exercise
Study NCT03450239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI scan, including structural imaging, functional imaging (both task-related and structural), and Magnetic Resonance Spectroscopy.
Study NCT03902392 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NaturOx Group (A)
Description: Comparison between dietary supplement and placebo
Study NCT03902392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group (B)
Description: Comparison between dietary supplement and placebo
Study NCT03260907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6\~13.9mA).
Study NCT03260907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
Study NCT00609453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Treatment for Depression
Description: Weekly individual therapy sessions
Study NCT04173299 — intervention group
Intervention type: PROCEDURE
Intervention: early tips
Description: patients with early tips
Study NCT02030444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET-MRI and EBUS-TBNA
Study NCT01974336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Study NCT00183937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS 341
Description: PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
Study NCT00183937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
Study NCT02470390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
Study NCT00573404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
Study NCT00573404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study NCT00573404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT02175576 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard XP Bicruciate Knee System
Description: The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
Study NCT02175576 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard CR Knee System
Description: The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: intravenous vinorelbine (25 mg/m2 weekly)
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vinorelbine
Description: intravenous vinorelbine (25 mg/m2 weekly)
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
Study NCT01007942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trastuzumab
Description: intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
Study NCT03565393 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Fibersol-2
Description: A placebo-controlled, randomized; double-blind 2 arm trial
Study NCT05209217 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Intranasal administration of their customary prescribed dose
Study NCT00413686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7762
Description: intravenous infusion
Study NCT00413686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: weekly intravenous infusion
Study NCT04132583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflox®
Description: Participants received a single oral dose of 50 mg Deflox® tablet in either treatment period 1 or 2 under fasting conditions.
Study NCT04132583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cataflam DD®
Description: Participants received a single oral dose of 50 mg Cataflam DD® tablet in either treatment period 1 or 2 under fasting conditions.
Study NCT02972918 — intervention group
Intervention type: DRUG
Intervention: Levosimendan
Description: 24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
Study NCT02502773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxethyl starch
Study NCT02267668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: Physical therapists guide participants through novel set of assigned exercises
Study NCT02267668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants self-guide through standard exercises
Study NCT03976583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cpp-Acp
Description: Remineralising agent
Study NCT03976583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pearl powder
Description: Natural product
Study NCT03844958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Furu
Description: 50 g red furu was consumed with 2 slices of plain bread for one-day~50 g Fresh tofu was consumed with 2 slices of plain bread for one-day
Study NCT03844958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tofu
Description: 50 g Fresh tofu was consumed with 2 slices of plain bread for one-day~50 g red furu was consumed with 2 slices of plain bread for one-day
Study NCT02107820 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Training (BT)
Description: All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
Study NCT02107820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve stimulation
Description: A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each.
Study NCT02107820 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Tibial Nerve stimulation
Description: A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each.
Study NCT04526886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Description: Chemotherapy dose-adjustment algorithm for FOLFOX chemotherapy
Study NCT02894437 — intervention group
Intervention type: OTHER
Intervention: qualitative interviews
Description: semi-structured interviews as a conceptual frame work
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 620 mg single dose
Description: metformin glycinate 620 mg single dose
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 1240 mg single dose
Description: metformin glycinate 1240 mg single dose
Study NCT00429871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 2480 mg single dose
Description: metformin glycinate 2480 mg single dose
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step A: metformin hydrochloride 1000 mg single dose
Description: metformin Chlorhydrate 1000 mg single dose
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step A: metformin glycinate 1240 mg,food intake
Description: metformin glycinate 1240 mg, intake of food
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Step B: metformin glycinate 620 mg BID
Description: metformin glycinate 620 mg BID, 8 days
Study NCT01560481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Step B: metformin hydrochloride 500 mg BID
Description: metformin Chlorhydrate 500 mg BID, 8 days
Study NCT00193427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
Study NCT00193427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
Study NCT00193427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC = 1.5 weekly x 7
Study NCT00193427 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: To 63 Gy
Study NCT02572011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Games Console Balance Training
Description: The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
Study NCT00429871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
Study NCT00429871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
Study NCT01321853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MD2 machine and nurse care coordination
Description: MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
Study NCT01321853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medplanner and Nurse Care Coordination
Description: Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
Study NCT03204604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Challenge A - low calorie Ensure®
Description: Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
Study NCT03204604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Challenge B - Ensure® plus ketone esters (KE)
Description: Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
Study NCT03204604 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET Scan
Description: Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of \[11C\]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using \[11C\]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post \[11C\]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period